ACER [delisted] Acer Therapeutics Inc

Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals

NASDAQ | Common Stock

Price
$N/A
Increased by 0.00%
Dollar volume (20D)
N/A
ADR%
N/A
Shares float
18.37 M
Shares short
493.55 K [2.69%]
Shares outstanding
24.46 M
Market cap
16.15 M
Beta
0.44
Price/earnings
N/A

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases.

The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease.

It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder.

The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

As of November 17, 2023, Acer Therapeutics Inc. operates as a subsidiary of Zevra Therapeutics, Inc.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 20, 23 -0.60
Decreased by -93.55%
-0.12
Decreased by -400.00%
Aug 14, 23 -0.33
Decreased by -94.12%
-0.25
Decreased by -32.00%
May 15, 23 -0.77
Decreased by -20.31%
-0.28
Decreased by -175.00%
Mar 27, 23 -0.54
Decreased by -74.19%
-0.37
Decreased by -45.95%
Nov 14, 22 -0.31
Decreased by -34.78%
-0.68
Increased by +54.41%
Aug 15, 22 -0.17
Increased by +26.09%
-0.57
Increased by +70.18%
May 16, 22 -0.64
Decreased by -481.82%
-0.41
Decreased by -56.10%
Mar 2, 22 -0.31
Increased by +38.00%
-0.01
Decreased by -3.00 K%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 371.79 K
Increased by +N/A%
-14.73 M
Decreased by -195.36%
Decreased by -3.96 K%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-8.09 M
Decreased by -220.07%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-26.86 M
Decreased by -192.52%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by -100.00%
-11.24 M
Decreased by -154.25%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-4.99 M
Decreased by -52.38%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-2.53 M
Increased by +21.67%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by -100.00%
-9.18 M
Decreased by -506.79%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 360.00 K
Increased by +N/A%
-4.42 M
Increased by +29.13%
Decreased by -1.23 K%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY